Therapeutic Advances in Medical OncologyEfficacy of Immunotherapy in Oncogene-driven Non-small-cell Lung Cancer

The article discusses the expanding landscape of targeted therapies for patients with advanced metastatic non-small-cell lung cancer (NSCLC), with nine targetable oncogenes and seven approvals within the last five years. With these emerging therapeutic options, the article emphasizes the importance of understanding the existing data on immune checkpoint inhibitors (ICIs) for each oncogene-driven lung cancer to guide the selection and sequencing of therapeutic options. The article reviews the clinical data on ICIs for each of the driver oncogene-defined lung cancer subtypes, including efficacy, toxicities, and potential strategies to enhance ICI efficacy in oncogene-driven NSCLC.